Arteritis. Giant Cell. Biologic Therapy. Sunday, November 5, 2017 Hilton San Diego Bayfront Sapphire M/N Ballroom, 4th Floor San Diego, CA

Transcription

1

2 Overview Learning Objectives Giant cell arteritis (GCA) is the most common form of medium- and large-vessel vasculitis. If left untreated, patients with GCA are at increased risk for a range of short- and longterm complications. Diagnosis of GCA remains difficult due to the non-specific nature of many early symptoms. Until recently, therapeutic options were limited to prolonged, high-dose glucocorticoid therapy, which has the potential for many undesirable side effects. In this CME activity, expert will discuss the clinical and immunopathologic features of GCA, current therapeutic options, as well as data for new and emerging agents. Case-based discussion will provide practical strategies for overcoming the diagnostic and treatment challenges of GCA. Upon successful completion of this activity, participants should be better able to: Review the pathophysiology and clinical symptomology of GCA. Examine the short- and long-term complications associated with GCA as well as the importance of early diagnosis and treatment. Identify patients with GCA in a timely and accurate manner based on appropriate clinical work-up and diagnostic modalities. Examine the advantages and disadvantages of conventional treatments for the management of GCA and related vasculitides. Apply knowledge of the latest clinical evidence to the optimal treatment of patients with GCA. Target Audience The intended audience for this activity is rheumatologists and other health care professionals involved in the treatment of patients with GCA. Agenda 6:40 Introduction and Pretest 6:40 7:05 Clinical and Immunopathologic Aspects of GCA: Implications for Diagnosis and Treatment 7:05 7:25 Current Treatment Paradigms for GCA and Unmet Patient Needs 7:25 7:50 New and Emerging Biologics for GCA Management 7:50 8:10 8:30 8:10 Clinical Cases: Panel Discussion Posttest and Question and Answer Meeting Adjournment Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Vindico Medical Education designates this live activity for a maximum of AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity. In accordance with the Accreditation Council for Continuing Medical Education s Standards for Commercial Support, all planners, teachers, and authors involved in the develoent of CME content are required to disclose to the accredited provider their relevant financial relationships. Relevant financial relationships will be disclosed to the activity audience. Faculty, topics, program schedule, and credit hours are subject to change. Audiotaping or videotaping is prohibited without written permission from the Program Committee istockphoto.com/ysuel; eraxion; vanastar Preferred Mailing Address (Home/Business) State Zip Code Country Daytime Phone Evening Phone Fax Date of Birth Contact Information: MeetingRegistration@VindicoCME.com Degree (please specify) q PharmD/RPh q PA q RN/BSN/MSN q NP q Industry q Other: Phone: , ext. 219 or 476 Fax: How did you hear about this meeting? Mail: Registration Department 6900 Grove Road Priority Code: (for tracking credits ONLY) National Provider Identifier (NPI) Medical License Number Medical License State q MD/DO q PhD q MD, PhD Toll-free: , ext. 219 or 476 First Name M.I. Last Name City (multiple selections allowed) q q Advertisement q Postcard q Brochure q Web site q Word of mouth Specialty (select one) q Rheumatology q Internal Medicine q Family Practice q Other: CME Activity Request q YES, I would like to receive information regarding future CME activities related to this therapeutic area. ADA compliance: In compliance with the Americans with Disabilities Act of 1990, we will make reasonable efforts to accommodate persons with disabilities. Please call with your requests.

3

4 Overview Learning Objectives Giant cell arteritis (GCA) is the most common form of medium- and large-vessel vasculitis. If left untreated, patients with GCA are at increased risk for a range of short- and longterm complications. Diagnosis of GCA remains difficult due to the non-specific nature of many early symptoms. Until recently, therapeutic options were limited to prolonged, high-dose glucocorticoid therapy, which has the potential for many undesirable side effects. In this CME activity, expert will discuss the clinical and immunopathologic features of GCA, current therapeutic options, as well as data for new and emerging agents. Case-based discussion will provide practical strategies for overcoming the diagnostic and treatment challenges of GCA. Upon successful completion of this activity, participants should be better able to: Review the pathophysiology and clinical symptomology of GCA. Examine the short- and long-term complications associated with GCA as well as the importance of early diagnosis and treatment. Identify patients with GCA in a timely and accurate manner based on appropriate clinical work-up and diagnostic modalities. Examine the advantages and disadvantages of conventional treatments for the management of GCA and related vasculitides. Apply knowledge of the latest clinical evidence to the optimal treatment of patients with GCA. Target Audience The intended audience for this activity is rheumatologists and other health care professionals involved in the treatment of patients with GCA. Agenda 6:40 Introduction and Pretest 6:40 7:05 Clinical and Immunopathologic Aspects of GCA: Implications for Diagnosis and Treatment 7:05 7:25 Current Treatment Paradigms for GCA and Unmet Patient Needs 7:25 7:50 New and Emerging Biologics for GCA Management 7:50 8:10 8:30 8:10 Clinical Cases: Panel Discussion Posttest and Question and Answer Meeting Adjournment Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Vindico Medical Education designates this live activity for a maximum of AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity. In accordance with the Accreditation Council for Continuing Medical Education s Standards for Commercial Support, all planners, teachers, and authors involved in the develoent of CME content are required to disclose to the accredited provider their relevant financial relationships. Relevant financial relationships will be disclosed to the activity audience. Faculty, topics, program schedule, and credit hours are subject to change. Audiotaping or videotaping is prohibited without written permission from the Program Committee istockphoto.com/ysuel; eraxion; vanastar Preferred Mailing Address (Home/Business) State Zip Code Country Daytime Phone Evening Phone Fax Date of Birth Contact Information: MeetingRegistration@VindicoCME.com Degree (please specify) q PharmD/RPh q PA q RN/BSN/MSN q NP q Industry q Other: Phone: , ext. 219 or 476 Fax: How did you hear about this meeting? Mail: Registration Department 6900 Grove Road Priority Code: (for tracking credits ONLY) National Provider Identifier (NPI) Medical License Number Medical License State q MD/DO q PhD q MD, PhD Toll-free: , ext. 219 or 476 First Name M.I. Last Name City (multiple selections allowed) q q Advertisement q Postcard q Brochure q Web site q Word of mouth Specialty (select one) q Rheumatology q Internal Medicine q Family Practice q Other: CME Activity Request q YES, I would like to receive information regarding future CME activities related to this therapeutic area. ADA compliance: In compliance with the Americans with Disabilities Act of 1990, we will make reasonable efforts to accommodate persons with disabilities. Please call with your requests.

5